PubMed (RefSeq) for id: 50511930

Year	Number of Results
1988	1
1989	3
1990	2
1993	1
1995	2
1996	3
1997	3
1998	3
1999	2
2000	1
2001	8
2002	8
2003	6
2004	8
2005	9
2006	19
2007	9
2008	11
2009	15
2010	14
2011	19
2012	11
2013	14
2014	19
2015	11
2016	9
2017	6
2018	4
2019	4
2020	6
2021	10
2022	2
2023	6
2024	2

1

FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment.

Knorr DA, Blanchard L, Leidner RS, Jensen SM, Meng R, Jones A, Ballesteros-Merino C, Bell RB, Baez M, Marino A, Sprott D, Bifulco CB, Piening B, Dahan R, Osorio JC, Fox BA, Ravetch JV. Knorr DA, et al. Cancer Immunol Res. 2024 Mar 4;12(3):322-333. doi: 10.1158/2326-6066.CIR-23-0389. Cancer Immunol Res. 2024. PMID: 38147316 Free PMC article.

2

C-reactive protein impairs immune response of CD8⁺ T cells via FcγRIIb-p38MAPK-ROS axis in multiple myeloma.

Jiang J, Peng Z, Wang J, Chen M, Wan Y, Huang H, Liu Z, Wang J, Hou J. Jiang J, et al. J Immunother Cancer. 2023 Oct;11(10):e007593. doi: 10.1136/jitc-2023-007593. J Immunother Cancer. 2023. PMID: 37844994 Free PMC article.

3

FCGR2B as a prognostic and immune microenvironmental marker for gliomas based on transcriptomic analysis.

Sun Z, Sun X, Yuan Y, Li H, Li X, Yao Z. Sun Z, et al. Medicine (Baltimore). 2023 Sep 15;102(37):e35084. doi: 10.1097/MD.0000000000035084. Medicine (Baltimore). 2023. PMID: 37713871 Free PMC article.

4

FcγRIIB expression increases during primary biliary cholangitis.

Gao X, Ma H, Niu J, Li D. Gao X, et al. Mol Immunol. 2023 Oct;162:30-37. doi: 10.1016/j.molimm.2023.08.001. Epub 2023 Aug 25. Mol Immunol. 2023. PMID: 37634276

5

FcγRIIB expressed on CD8⁺ T cells limits responsiveness to PD-1 checkpoint inhibition in cancer.

Bennion KB, Tariq M, Wyatt MM, Duneton C, Baecher KM, Paulos CM, Kudchadkar RR, Lowe MC, Ford ML. Bennion KB, et al. Sci Transl Med. 2023 Aug 23;15(710):eadd1868. doi: 10.1126/scitranslmed.add1868. Epub 2023 Aug 23. Sci Transl Med. 2023. PMID: 37611081

6

Mutation of the TGN1412 anti-CD28 monoclonal antibody lower hinge confers specific FcγRIIb binding and retention of super-agonist activity.

Chenoweth AM, Esparon S, Wines BD, Schuurman J, Labrijn AF, Hogarth PM. Chenoweth AM, et al. Immunol Cell Biol. 2023 Aug;101(7):657-662. doi: 10.1111/imcb.12646. Epub 2023 Apr 28. Immunol Cell Biol. 2023. PMID: 36997299 Free PMC article.

7

FCGR2A as one novel potential target for poor survival prognosis of clear cell renal cell carcinoma.

Fu T, Zhang L, Zuo M, Li F, Shi C, Chen H. Fu T, et al. Medicine (Baltimore). 2023 Mar 17;102(11):e33324. doi: 10.1097/MD.0000000000033324. Medicine (Baltimore). 2023. PMID: 36930102 Free PMC article.

8

FcγRIIB potentiates differentiation of myeloid-derived suppressor cells to mediate tumor immunoescape.

Wu L, Xu Y, Zhao H, Zhou Y, Chen Y, Yang S, Lei J, Zhang J, Wang J, Wu Y, Li Y. Wu L, et al. Theranostics. 2022 Jan 1;12(2):842-858. doi: 10.7150/thno.66575. eCollection 2022. Theranostics. 2022. PMID: 34976216 Free PMC article.

9

Impacts of FcγRIIB and FcγRIIIA gene polymorphisms on systemic lupus erythematous disease activity index.

Karimifar M, Akbari K, ArefNezhad R, Fathi F, Mousaei Ghasroldasht M, Motedayyen H. Karimifar M, et al. BMC Res Notes. 2021 Dec 18;14(1):455. doi: 10.1186/s13104-021-05868-2. BMC Res Notes. 2021. PMID: 34922596 Free PMC article.

10

The association between Fc gamma RIIb expression levels and chronic hepatitis B virus infection progression.

Jin J, Liu Y, Xu X, Wang Z, Niu J. Jin J, et al. BMC Infect Dis. 2021 Dec 8;21(1):1235. doi: 10.1186/s12879-021-06918-7. BMC Infect Dis. 2021. PMID: 34879827 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

226 results

Results by year